Doxorex 2mg injection

Doxorex 2mg Injection is a allopathy based anticancer medication that is used to treat various cancers including blood cancers (leukemias, lymphomas, multiple myeloma), breast cancer, ovarian cancer, and others like lung, stomach, thyroid, sarcomas, and AIDS-related Kaposi's sarcoma. Doxorex 2mg Injection contains Pegylated Lipososmal Doxorubicin Hydrochloride that damage DNA and cell membranes leading to cancer cell death.

Like any other chemical based medication, Doxorex 2mg Injection also has certain common side effects. Consult your doctor, if side effects persist for longer period of time.
● Headache
● Cough
● Diarrhea
● Nausea
● Weakness
● Itchy skin or rash
● Shortness of breath
● Decreased appetite
● Infection in the nose or throat
● Fever
● Pain in your muscles, bones, and joints
● Heart problems
● Bone Marrow Supression
● Secondary Leukaemia Risk
● Severe Allergic Reactions

Doxorex 2mg Injection is administered intravenously (In Veins) by a doctor or an experienced nurse. It is advice not to self administer the injection on your own. For personalized dosage ask your doctor about the same. As Dosage is entirely based on the body surface area, type of cancer, its stage as well as patient's overall health.

Doxorex 2mg Injection contains Pegylated Lipososmal Doxorubicin Hydrochloride that works by inhibiting the enzyme topoisomerase II, which is essential for DNA replication in cancer cells. It also damages DNA and cell membranes leading to cancer cell death.

• Rivankar, S. (2014). An overview of doxorubicin formulations in cancer therapy. Journal of cancer research and therapeutics, 10(4), 853-858.
• Vigevani, A., & Williamson, M. J. (1981). Doxorubicin. In Analytical profiles of drug substances (Vol. 9, pp. 245-274). Academic Press.
• Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003). Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clinical pharmacokinetics, 42(5), 419-436.
• Ansari, L., Shiehzadeh, F., Taherzadeh, Z., Nikoofal-Sahlabadi, S., Momtazi-Borojeni, A. A., Sahebkar, A., & Eslami, S. (2017). The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: a systematic review of clinical trials. Cancer gene therapy, 24(5), 189-193.